Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
NervGen Pharma ( (TSE:NGEN) ) has shared an update.
NervGen Pharma said it will voluntarily delist its common shares from the TSX Venture Exchange effective March 16, 2026, while maintaining its Nasdaq listing under the symbol NGEN. The company, which will remain a Canadian reporting issuer, emphasized that all shareholders, including those in Canada, will retain full trading access via Nasdaq and need not take any action.
Management framed the move as a cost- and complexity-reduction strategy as NervGen advances late-stage development of NVG-291, arguing that dual listing no longer justifies the added legal, accounting, and regulatory burden. In conjunction with the delisting, NervGen terminated its at-the-market equity program, after issuing only 245 shares for net proceeds of $1,489, underscoring a shift in focus toward clinical execution and long-term shareholder value rather than incremental equity raises under the facility.
The most recent analyst rating on (TSE:NGEN) stock is a Buy with a C$6.75 price target. To see the full list of analyst forecasts on NervGen Pharma stock, see the TSE:NGEN Stock Forecast page.
Spark’s Take on TSE:NGEN Stock
According to Spark, TipRanks’ AI Analyst, TSE:NGEN is a Neutral.
Score is held back primarily by weak financial performance (pre-revenue, widening losses, heavy cash burn, and negative equity). Offsetting factors include strong technical momentum (price above major moving averages with positive MACD) and constructive corporate catalysts (clinical/regulatory progress and new financing), while valuation remains constrained by lack of profitability and no dividend support.
To see Spark’s full report on TSE:NGEN stock, click here.
More about NervGen Pharma
NervGen Pharma is a Vancouver-based clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurotraumatic and neurologic conditions. Its lead candidate, NVG-291, a subcutaneous neuroreparative peptide with FDA Fast Track and EMA Orphan Drug designations, has shown durable functional improvements in chronic SCI and is advancing toward Phase 3, alongside an ongoing subacute SCI study and next-generation candidate NVG-300.
Average Trading Volume: 93,862
Technical Sentiment Signal: Buy
Current Market Cap: C$425.8M
For an in-depth examination of NGEN stock, go to TipRanks’ Overview page.